BIOGEN INC (IDP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:IDP - US09062X1037 - Common Stock
157.05 EUR
+1.15 (+0.74%)
Overall IDP gets a fundamental rating of 5 out of 10. We evaluated IDP against 82 industry peers in the Biotechnology industry. IDP has an excellent financial health rating, but there are some minor concerns on its profitability. IDP is valued quite cheap, but it does not seem to be growing. This makes IDP very considerable for value investing!
1. Profitability
1.1 Basic Checks
IDP had positive earnings in the past year.
IDP had a positive operating cash flow in the past year.
IDP had positive earnings in each of the past 5 years.
IDP had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
IDP has a better Return On Assets (5.51%) than 79.52% of its industry peers.
IDP has a better Return On Equity (8.84%) than 79.52% of its industry peers.
IDP has a better Return On Invested Capital (9.70%) than 86.75% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IDP is below the industry average of 13.22%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
IDP's Profit Margin of 15.98% is amongst the best of the industry. IDP outperforms 81.93% of its industry peers.
In the last couple of years the Profit Margin of IDP has declined.
Looking at the Operating Margin, with a value of 28.50%, IDP belongs to the top of the industry, outperforming 87.95% of the companies in the same industry.
In the last couple of years the Operating Margin of IDP has declined.
IDP has a Gross Margin of 75.24%. This is in the better half of the industry: IDP outperforms 66.27% of its industry peers.
In the last couple of years the Gross Margin of IDP has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IDP is still creating some value.
The number of shares outstanding for IDP has been increased compared to 1 year ago.
IDP has less shares outstanding than it did 5 years ago.
IDP has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.35 indicates that IDP is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 3.35, IDP is doing good in the industry, outperforming 73.49% of the companies in the same industry.
IDP has a debt to FCF ratio of 2.78. This is a good value and a sign of high solvency as IDP would need 2.78 years to pay back of all of its debts.
IDP has a Debt to FCF ratio of 2.78. This is amongst the best in the industry. IDP outperforms 80.72% of its industry peers.
IDP has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.35, IDP perfoms like the industry average, outperforming 49.40% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.35 |
ROIC/WACC1.17
WACC8.27%
2.3 Liquidity
IDP has a Current Ratio of 2.72. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.72, IDP perfoms like the industry average, outperforming 57.83% of the companies in the same industry.
A Quick Ratio of 2.04 indicates that IDP has no problem at all paying its short term obligations.
IDP has a Quick ratio of 2.04. This is comparable to the rest of the industry: IDP outperforms 49.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 2.51% over the past year.
IDP shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -13.31% yearly.
Looking at the last year, IDP shows a small growth in Revenue. The Revenue has grown by 4.77% in the last year.
Measured over the past years, IDP shows a decrease in Revenue. The Revenue has been decreasing by -7.62% on average per year.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
The Earnings Per Share is expected to grow by 0.56% on average over the next years.
IDP is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.63% yearly.
EPS Next Y-7.79%
EPS Next 2Y-3.43%
EPS Next 3Y-0.73%
EPS Next 5Y0.56%
Revenue Next Year1.98%
Revenue Next 2Y-1.74%
Revenue Next 3Y-1.31%
Revenue Next 5Y-0.63%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 10.92 indicates a reasonable valuation of IDP.
IDP's Price/Earnings ratio is rather cheap when compared to the industry. IDP is cheaper than 92.77% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.46. IDP is valued rather cheaply when compared to this.
A Price/Forward Earnings ratio of 11.91 indicates a reasonable valuation of IDP.
96.39% of the companies in the same industry are more expensive than IDP, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of IDP to the average of the S&P500 Index (36.10), we can say IDP is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.92 | ||
| Fwd PE | 11.91 |
4.2 Price Multiples
89.16% of the companies in the same industry are more expensive than IDP, based on the Enterprise Value to EBITDA ratio.
IDP's Price/Free Cash Flow ratio is rather cheap when compared to the industry. IDP is cheaper than 91.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.86 | ||
| EV/EBITDA | 8 |
4.3 Compensation for Growth
The decent profitability rating of IDP may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.43%
EPS Next 3Y-0.73%
5. Dividend
5.1 Amount
IDP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:IDP (12/5/2025, 7:00:00 PM)
157.05
+1.15 (+0.74%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners95.4%
Inst Owner ChangeN/A
Ins Owners0.14%
Ins Owner ChangeN/A
Market Cap23.04B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts74.29
Price Target155.46 (-1.01%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)3.36%
PT rev (3m)6.14%
EPS NQ rev (1m)0.29%
EPS NQ rev (3m)-54.42%
EPS NY rev (1m)-2.12%
EPS NY rev (3m)-6.19%
Revenue NQ rev (1m)-0.09%
Revenue NQ rev (3m)-2.22%
Revenue NY rev (1m)0.62%
Revenue NY rev (3m)1.58%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.92 | ||
| Fwd PE | 11.91 | ||
| P/S | 2.67 | ||
| P/FCF | 11.86 | ||
| P/OCF | 10.93 | ||
| P/B | 1.47 | ||
| P/tB | 11.25 | ||
| EV/EBITDA | 8 |
EPS(TTM)14.38
EY9.16%
EPS(NY)13.19
Fwd EY8.4%
FCF(TTM)13.24
FCFY8.43%
OCF(TTM)14.36
OCFY9.15%
SpS58.92
BVpS106.58
TBVpS13.96
PEG (NY)N/A
PEG (5Y)N/A
Graham Number185.7
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.44% | ||
| ROICexgc | 40.96% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% | ||
| FCFM | 22.48% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25.04% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.56% | ||
| Profit Quality | 140.63% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.35 |
F-Score5
WACC8.27%
ROIC/WACC1.17
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-7.79%
EPS Next 2Y-3.43%
EPS Next 3Y-0.73%
EPS Next 5Y0.56%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.98%
Revenue Next 2Y-1.74%
Revenue Next 3Y-1.31%
Revenue Next 5Y-0.63%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year4.94%
EBIT Next 3Y-0.22%
EBIT Next 5Y1.51%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%
BIOGEN INC / IDP.DE FAQ
What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to IDP.DE.
Can you provide the valuation status for BIOGEN INC?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.
What is the profitability of IDP stock?
BIOGEN INC (IDP.DE) has a profitability rating of 6 / 10.
Can you provide the financial health for IDP stock?
The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.
Can you provide the expected EPS growth for IDP stock?
The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to decline by -7.79% in the next year.